Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial

Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown. We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose prenatal 3rd...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nutrition journal 2013-04, Vol.12 (1), p.47-47, Article 47
Hauptverfasser:	Roth, Daniel E, Al Mahmud, Abdullah, Raqib, Rubhana, Akhtar, Evana, Perumal, Nandita, Pezzack, Brendon, Baqui, Abdullah H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Alfacalcidol Bangladesh Blood pressure Calcifediol Calcium - blood Calcium - urine Cholecalciferol - administration & dosage Cholecalciferol - pharmacokinetics Clinical trials Creatinine - urine Cross-Sectional Studies Dietary Supplements Disease Dose-Response Relationship, Drug Double-Blind Method Drug dosages Female Fetal Blood - chemistry Health aspects Hospitals Humans Infant, Newborn Infants (Newborn) Linear Models Mortality Parathyroid Hormone - blood Pregnancy Pregnancy Outcome Pregnancy Trimester, Third Pregnant women Serum Albumin - metabolism Vitamin D Vitamin D - analogs & derivatives Vitamin D - blood Vitamin D - pharmacokinetics Womens health Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown. We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose prenatal 3rd trimester vitamin D3 supplementation on maternal and neonatal (cord blood) serum 25-hydroxyvitamin D (25(OH)D) concentration (primary biochemical efficacy outcome) and maternal serum calcium concentration (primary safety measure). Eligibility criteria were pregnant women aged 18 to
ISSN:	1475-2891 1475-2891
DOI:	10.1186/1475-2891-12-47